27235977|t|Laser -facilitated epicutaneous immunotherapy to IgE-mediated allergy
27235977|a|Allergen specific immunotherapy has been shown to be the only effective treatment for long-lasting clinical benefit to IgE-mediated allergic diseases, but a fewer than 5% of patients choose the treatment because of inconvenience and a high risk of anaphylaxis. Recently, epicutaneous allergen-specific immunotherapy (EPIT) has proven effective, yet with limitations owing to strong skin reactions. We demonstrate here safer and faster EPIT, named μEPIT, by delivering powdered allergen and adjuvants into many micropores in the epidermis. We fabricated a microarray patch fractionally coated with a powder mixture of ovalbumin (OVA) model allergen, CpG, and 1,25-dihydroxyvitamin D3 (VD3). Topical application of the patch onto laser-microperforated skin resulted in a high level of epidermal delivery while greatly minimizing allergen leakage into circulation system as compared to current subcutaneous immunotherapy (SCIT). Moreover, only three times of μEPIT over two weeks could sufficiently inhibit allergen-specific IgE responses in mice suffering OVA -induced airway hyperresponsivness (AHR), which was unattainable by eight times of SCIT over three weeks. Mechanistically, μEPIT preferably enhanced IgG2a production suggesting TH1-biased immune responses and induced a high level of T-regulatory (Treg) cells against repeated allergen sensitization. The immune tolerance was confirmed by marked reduction in airway wall thickness as well as eosinophil and neutrophil infiltration into the respiratory airway. The μEPIT represents a novel and painless technology to treat IgE-mediated allergic diseases with little local skin reaction and a minimal risk of anaphylaxis.
27235977	0	5	Laser	T073	C0023089
27235977	19	31	epicutaneous	T061	C0001558
27235977	32	45	immunotherapy	T061	C0021083
27235977	49	69	IgE-mediated allergy	T047	C1706410
27235977	70	101	Allergen specific immunotherapy	T061	C0162352
27235977	132	141	effective	T080	C1704419
27235977	142	151	treatment	T061	C0087111
27235977	156	168	long-lasting	T079	C0443252
27235977	169	177	clinical	T080	C0205210
27235977	178	185	benefit	T081	C0814225
27235977	189	219	IgE-mediated allergic diseases	T047	C1706410
27235977	244	252	patients	T101	C0030705
27235977	264	273	treatment	T061	C0087111
27235977	305	317	high risk of	T033	C0332167
27235977	318	329	anaphylaxis	T046	C0002792
27235977	341	385	epicutaneous allergen-specific immunotherapy	T061	C0162352
27235977	387	391	EPIT	T061	C0162352
27235977	404	413	effective	T080	C1704419
27235977	424	435	limitations	T169	C0449295
27235977	445	466	strong skin reactions	T201	C0221743
27235977	505	509	EPIT	T061	C0162352
27235977	517	522	μEPIT	T061	C0162352
27235977	527	537	delivering	T169	C1705822
27235977	538	555	powdered allergen	T129	C0002092
27235977	560	569	adjuvants	T121,T129	C0001551
27235977	580	590	micropores	T026	C1325742
27235977	598	607	epidermis	T024	C0014520
27235977	625	635	microarray	T073	C1709016
27235977	636	641	patch	T074	C0991556
27235977	655	661	coated	T080	C1522408
27235977	669	696	powder mixture of ovalbumin	T116,T123	C0029923
27235977	698	701	OVA	T116,T123	C0029923
27235977	709	717	allergen	T129	C0002092
27235977	719	722	CpG	T114,T123	C0056912
27235977	728	752	1,25-dihydroxyvitamin D3	T109,T121,T127	C0006674
27235977	754	757	VD3	T109,T121,T127	C0006674
27235977	760	779	Topical application	T061	C0683174
27235977	787	792	patch	T074	C0991556
27235977	798	819	laser-microperforated	T033	C1709025
27235977	820	824	skin	T022	C1123023
27235977	825	836	resulted in	T169	C0332294
27235977	844	849	level	T080	C0441889
27235977	853	862	epidermal	T024	C0014520
27235977	863	871	delivery	T169	C1705822
27235977	897	905	allergen	T129	C0002092
27235977	906	913	leakage	T033	C4281748
27235977	919	937	circulation system	T022	C0007226
27235977	941	949	compared	T052	C1707455
27235977	961	987	subcutaneous immunotherapy	T061	C0413381
27235977	989	993	SCIT	T061	C0413381
27235977	1026	1031	μEPIT	T061	C0162352
27235977	1066	1073	inhibit	T052	C3463820
27235977	1074	1095	allergen-specific IgE	T116,T129	C0443736
27235977	1096	1105	responses	T032	C0871261
27235977	1109	1113	mice	T015	C0025929
27235977	1124	1127	OVA	T116,T123	C0029923
27235977	1137	1162	airway hyperresponsivness	T046	C0035228
27235977	1164	1167	AHR	T046	C0035228
27235977	1211	1215	SCIT	T061	C0413381
27235977	1251	1256	μEPIT	T061	C0162352
27235977	1268	1276	enhanced	T052	C2349975
27235977	1277	1282	IgG2a	T116,T129	C0020857
27235977	1283	1293	production	T038	C0003261
27235977	1305	1315	TH1-biased	T025	C0242632
27235977	1316	1332	immune responses	T042	C0301872
27235977	1337	1344	induced	T169	C0205263
27235977	1352	1357	level	T080	C0441889
27235977	1361	1373	T-regulatory	T025	C0039198
27235977	1375	1379	Treg	T025	C0039198
27235977	1381	1386	cells	T025	C0007634
27235977	1404	1426	allergen sensitization	T047	C2938930
27235977	1432	1448	immune tolerance	T046	C0020963
27235977	1453	1465	confirmed by	T080	C0521093
27235977	1473	1482	reduction	T061	C0441610
27235977	1486	1497	airway wall	T023	C0458827
27235977	1498	1507	thickness	T033	C0205400
27235977	1519	1529	eosinophil	T025	C0014467
27235977	1534	1557	neutrophil infiltration	T039	C0751982
27235977	1567	1585	respiratory airway	T023	C0282335
27235977	1591	1596	μEPIT	T061	C0162352
27235977	1597	1607	represents	T052	C1882932
27235977	1610	1615	novel	T080	C0205314
27235977	1620	1628	painless	T169	C0234226
27235977	1629	1639	technology	T090	C0039421
27235977	1643	1648	treat	T061	C0087111
27235977	1649	1679	IgE-mediated allergic diseases	T047	C1706410
27235977	1692	1711	local skin reaction	T201	C0221743
27235977	1734	1745	anaphylaxis	T046	C0002792